Change over period: —
NSE · HCG
HCG
-19.7% from the 52-week high · +14.9% above the low
HealthCare Global Enterprises Ltd. provides imaging and diagnostics services for cancer treatment. The company is headquartered in Bangalore, Karnataka and currently employs 5,679 full-time employees. The company went IPO on 2016-03-30. The firm is involved retail sale of pharmaceuticals, medical and orthopedic goods and toilet articles. The company operates cancer care network under the HCG brand. The company operates infertility treatment clinics providing assisted reproductive services under brand Milann. The firm operates eight Milann fertility centers, which provide reproductive medicine services, including assisted reproduction, gynecological endoscopy and fertility preservation; and follow a multidisciplinary and technology-focused approach to diagnosis and treatment. Milann fertility centers also offer training programs for fertility specialists and embryologists. Under the Triesta brand, it provides clinical reference laboratory services with specialization in oncology.
The short version. HCG reported revenue of ₹732 crore for Sep 2026, up 13.1% from a year earlier. Net profit was ₹5 crore (down 68.8% year on year). Return on equity was 1.0% in Mar 2026. Promoter holding was 64.21% in Sep 2026, down 7.01 points over 8 quarters.
1 · The price
How has the stock traded?
HCG trades 19.7% below its 52-week high and 14.9% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹732 cr.
Sep 2026 net profit of ₹5 cr.
1.8 pts lower than a year earlier.
Revenue compounded at 14.6% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 732 | 695 | 652 | 633 | 647 | 613 | 585 | 558 |
| Net profit | 5 | 14 | 2 | -9 | 16 | 5 | 7 | 7 |
| Net margin % | 0.7 | 2.0 | 0.3 | -1.5 | 2.5 | 0.8 | 1.3 | 1.3 |
| EPS (₹) | 0.32 | 0.92 | 0.15 | -0.63 | 1.09 | 0.32 | 0.5 | 0.47 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2545 | 2223 | 1912 | 1694 | 1398 | 1013 | 1096 | 976 |
| Net profit | 14 | 44 | 48 | 29 | 54 | -193 | -107 | -25 |
| Net margin % | 0.5 | 2.0 | 2.5 | 1.7 | 3.8 | -19.1 | -9.7 | -2.5 |
| EPS (₹) | 0.92 | 3.01 | 3.26 | 1.99 | 3.65 | -14.58 | -11.36 | -2.66 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 1.0% in Mar 2026; debt to equity is 0.68.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 1.0 | 4.8 | 5.8 | 3.4 |
| Return on capital % | 6.9 | 8.4 | 9.0 | 8.5 |
| EBITDA margin % | 17.4 | 18.7 | 18.2 | 18.3 |
| Net margin % | 0.5 | 2.0 | 2.5 | 1.7 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 14.6% | 20.1% |
| Profit CAGR | -22.3% | — |
4 · The owners
Who holds it, and are they adding?
Down 7.01 pts over 8 quarters.
Down 0.08 pts over 8 quarters.
Up 7.83 pts over 8 quarters.
+4 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 71.22 | 71.22 | 62.46 | 63.78 | 63.77 | 64.21 | 64.21 | 64.21 | -7.01 |
| FII | 2.77 | 2.45 | 2.16 | 3.59 | 3.22 | 2.75 | 2.74 | 2.69 | -0.08 |
| DII | 12.94 | 12.47 | 13.22 | 18.36 | 18.3 | 18.91 | 19.2 | 20.77 | +7.83 |
| Public | 13.06 | 13.86 | 22.16 | 14.27 | 14.71 | 14.13 | 13.85 | 12.32 | -0.74 |
Mutual fund holdings · Oct 2026
41 schemes hold this stock
37 the month before.
- TATA INDIA PHARMA & HEALTHCARE FUND5.25% of NAV
- Motilal Oswal Consumption Fund3.76% of NAV
- TATA FOCUSED FUND3.7% of NAV
- Nippon India ELSS Tax Saver Fund1.56% of NAV
- TATA AGGRESSIVE HYBRID FUND1.47% of NAV
- Groww BSE Hospitals ETF1.41% of NAV
- SBI Healthcare Opportunities Fund1.35% of NAV
- TATA CHILDRENS FUND1.2% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for HCG are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Healthcare Services stocks
Quick answers
Common questions about HCG
What is the HCG share price?
HCG (HCG) last closed at ₹614.05, up 2.45% on the day. Its 52-week range is ₹521.75 to ₹746.83.
What is the market cap of HCG?
HCG has a market capitalisation of about ₹8,931 crore.
How are HCG's latest results?
HCG reported revenue of ₹732 crore for Sep 2026, up 13.1% from a year earlier. Net profit was ₹5 crore (down 68.8% year on year). Return on equity was 1.0% in Mar 2026. Promoter holding was 64.21% in Sep 2026, down 7.01 points over 8 quarters.
Who owns HCG?
As of Sep 2026, shareholding was: Promoter 64.21%, FII 2.69%, DII 20.77%, Public 12.32%.
How many mutual funds hold HCG?
41 mutual fund schemes held HCG in October 2026. That compares with 37 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 02 Mar 2026 · Rights issue 1:17
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.